# A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)

> **NCT01554189** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 37 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** MK-8325
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01554189
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01554189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01554189, "A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01554189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*